ADVERTISEMENT

 

Late Breaking Abstracts

AUA2015 Webcasts

Plenary II - Sunday

Late Breaking Abstract (PII-LBA1): Using the Thermal Energy of Convectively Delivered Water Vapor for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: The Rezum II Study

Presenter: Kevin T. McVary, MD


Late Breaking Abstract (PII-LBA2): Validation of a Novel Non-Invasive Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients Undergoing Initial Biopsy with an Equivocal PSA

Presenter: James M. McKiernan, MD


Late Breaking Abstract (PII-LBA3): Glypican-1 as a Biomarker for Prostate Cancer

Presenter: Dr Jonathan Henderson

Presenter: Neal D. Shore, MD


Late Breaking Abstract (PII-LBA4): TERRAIN Trial: Prostate-specific Antigen Kinetics and Quality of Life Results of Enzalutamide versus Bicalutamide in Metastatic Castration-resistant Prostate Cancer

Presenter: Neal D. Shore, MD

Presenter: Arnauld A. Villers, MD


Late Breaking Abstract (PII-LBA5): Evidence of Superior Quality of Life after Robotic Prostatectomy: Results from a Population-Based Analysis

Presenter: Brock B. O'Neil


Late Breaking Abstract (PII-LBA6): Effect of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men

Presenter: Gerald B. Brock, MD


Late Breaking Abstract (PII-LBA7): In Two Phase III Studies, EndroxalTM (enclomiphene citrate) Significantly Improves Total Testosterone Levels Compared to Androgel 1.62%, Without Suppression of Spermatogenesis and Testicular Function in Overweight Males with Secondary Hypogonadism

Presenter: Andrew R. McCullough, MD


Late Breaking Abstract (PII-LBA8): Use of Linear Discriminant Analysis in a Urine-based Test for Bladder Cancer Diagnosis

Presenter: Lai Yi Mandy Sin


Late Breaking Abstract (PII-LBA9): Efficacy and safety of mirabegron add-on treatment to solifenacin in incontinent OAB subjects with an inadequate response to initial 4-week solifenacin monotherapy

Presenter: Marcus Drake, MD


Late Breaking Abstract (PII-LBA10): A Multicenter Phase 2 Study of Enzalutamide (ENZA) versus Bicalutamide (BIC) in Men with Nonmetastatic (M0) or Metastatic (M1) Castration-Resistant Prostate Cancer (CRPC): the STRIVE Trial

Presenter: Celestia S. Higano ,M.D.